Phase 2 Breast Cancer Trial, Recruiting NCT07180160 Sponsor: Wenjin Yin Condition: Breast Cancer
Back to Breast Cancer

Phase 2 Breast Cancer Trial, Recruiting

NCT07180160
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Women aged 18 years or older
  • People with an expected survival of at least 12 weeks
  • People with a good general level of physical functioning (a standard medical score of 0 or 1 on a scale used to measure daily activity ability)
  • People whose breast cancer has come back or spread to other parts of the body, confirmed by a tissue test, and where surgery to cure the disease is not possible
  • People whose breast cancer tests positive for hormone receptors (estrogen and/or progesterone) and negative for a protein called HER2
  • People who have at least one area of cancer that can be measured on a scan, or cancer that has spread only to the bones in a way that shows bone breakdown
  • People who have previously received no more than 2 courses of chemotherapy for advanced disease, and no more than 2 treatments from a specific class of cancer drugs called CDK4/6 inhibitors
  • People whose liver, kidneys, and other organs are working well enough to safely participate (confirm with trial site)

Who may not be able to join:

  • People who are currently pregnant or breastfeeding
  • People whose cancer has spread to the brain or central nervous system

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 12 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Wenjin Yin, M.D., Renji Hospital,School of Medicine, Shanghai Jiaotong University

Phone: 86(21)68385569

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Wenjin Yin
Registry
ClinicalTrials.gov
Start date
25 September 2025
Est. completion
1 September 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Progression-Free Survival (PFS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov